Individual generic drugmakers, including Mylan and Teva, were urged to step up their lobbying efforts at the leading generic drug trade group's meeting, according to Bloomberg Law.
During the Association for Accessible Medicine's meeting, which took place Feb. 5, leaders of the trade group emphasized that generic companies needed to increase the amount of time they spend with lawmakers and how much money they spent lobbying for policies that better suit generic makers.
In 2018, generic drug companies spent significantly less on lobbying than brand-name drug companies. For example, brand-name drugmakers Pfizer and Amgen spent $11.4 million and $10.9 million respectively. This compares to Mylan, which spent 2.9 million and Teva which spent $2.6 million.
"The risks at the federal level as well as at the state level where the generic industry has historically been under-represented are real," Chip Davis, head of the Association for Affordable Medicine, told drug company representatives at the meeting.